Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa P P, Ricci G, Verna R, Pannitteri G
Università degli Studi di Roma 'La Sapienza', Rome, Italy.
Eur J Clin Invest. 2002 Jan;32(1):9-15. doi: 10.1046/j.1365-2362.2002.00935.x.
The present study evaluated the role of the PON1 L55M polymorphism independently and in conjunction with the Q192R polymorphism on the risk of coronary atherosclerosis in an Italian population.
Three hundred and ninety-one subjects with significant coronary stenosis (> 50%) (coronary artery disease-positive; CAD+), 196 subjects with normal coronary arteries (< 10% stenosis) (CAD-) and 178 healthy controls were screened using a combination of polymerase chain reaction and restriction enzyme digestion.
In the pooled population, the frequencies of L and M alleles were 0.63 and 0.37, respectively; the most common haplotypes were QQ/LM (24.2%) and QR/LL (21.8%) and a strong linkage disequilibrium between L/55 and R/192 alleles was observed (D' = -0.91; P < 0.0001). CAD+ subjects did not show any significant differences in the distribution of PON1-55 genotypes as compared to CAD- subjects and population controls (chi2 = 1.5, P = 0.8). After controlling for other risk factors, the low-concentration M allele was not associated with a significant change of CAD risk (OR 1.02; 95% CI 0.80-1.29; P = 0.87). Moreover, the L55M polymorphism did not show any interaction with other risk factors such as smoking, diabetes, hypertension, low levels of high-density lipoprotein (HDL) or high ratios of low-density to high-density lipoproteins. The combination of L55M with the Q192R polymorphism did not show any effect on CAD risk. However, a marginal decrease in myocardial infarction risk was detected when QQ/MM carriers (OR 0.51; 95% CI 0.26-0.99; P = 0.048), but not LL/RR carriers, were compared with subjects not homozygous for an L or R allele.
These findings did not indicate a major effect of the PON1 L55M polymorphism, either alone or in combination with the Q192R polymorphism, on CAD risk. Additional studies are needed for a better evaluation of the role of the 55/192 PON1 genotypes in combination on myocardial infarction risk.
本研究评估了对氧磷酶1(PON1)L55M多态性单独以及与Q192R多态性共同作用对意大利人群冠状动脉粥样硬化风险的影响。
采用聚合酶链反应和限制性内切酶消化相结合的方法,对391例冠状动脉狭窄显著(>50%)(冠心病阳性;CAD+)的受试者、196例冠状动脉正常(狭窄<10%)(CAD-)的受试者以及178例健康对照进行筛查。
在汇总人群中,L和M等位基因的频率分别为0.63和0.37;最常见的单倍型为QQ/LM(24.2%)和QR/LL(21.8%),并且观察到L/55和R/192等位基因之间存在强连锁不平衡(D' = -0.91;P < 0.0001)。与CAD-受试者和人群对照相比,CAD+受试者在PON1 - 55基因型分布上未显示出任何显著差异(χ2 = 1.5,P = 0.8)。在控制其他危险因素后,低浓度的M等位基因与CAD风险的显著变化无关(比值比1.02;95%置信区间0.80 - 1.29;P = 0.87)。此外,L55M多态性与吸烟、糖尿病、高血压、高密度脂蛋白(HDL)水平低或低密度脂蛋白与高密度脂蛋白高比值等其他危险因素之间未显示出任何相互作用。L55M与Q192R多态性的组合对CAD风险未显示出任何影响。然而,当将QQ/MM携带者(比值比0.51;95%置信区间0.26 - 0.99;P = 0.048)与非L或R等位基因纯合子的受试者进行比较时,检测到心肌梗死风险有轻微降低,但LL/RR携带者未显示出这种情况。
这些发现并未表明PON1 L55M多态性单独或与Q192R多态性共同作用对CAD风险有重大影响。需要进一步研究以更好地评估PON1 55/192基因型组合对心肌梗死风险的作用。